NCT06058416View on ClinicalTrials.gov

Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

1,092

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

March 17, 2028

Study Completion Date

December 31, 2029

Conditions
Hepatitis A
Interventions
BIOLOGICAL

Healive (hepatitis A vacine(human diploid cell), inactivated)

"The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively."

Trial Locations (1)

Unknown

Liaoning Center for Disease Control and Prevention, Shenyang

All Listed Sponsors
collaborator

Liaoning Center for Disease Control and Prevention

OTHER

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT06058416 - Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old | Biotech Hunter | Biotech Hunter